Covestor Ltd Has $118,000 Holdings in Progyny, Inc. (NASDAQ:PGNY)

Covestor Ltd increased its position in Progyny, Inc. (NASDAQ:PGNY) by 69.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 6,868 shares of the company’s stock after purchasing an additional 2,814 shares during the period. Covestor Ltd’s holdings in Progyny were worth $118,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Signaturefd LLC grew its stake in Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock valued at $25,000 after acquiring an additional 1,355 shares in the last quarter. GAMMA Investing LLC grew its position in Progyny by 341.4% during the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after purchasing an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock valued at $51,000 after purchasing an additional 1,526 shares in the last quarter. Caitlin John LLC increased its stake in Progyny by 2,974.8% in the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock valued at $57,000 after buying an additional 3,183 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new stake in Progyny in the 4th quarter worth approximately $74,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on PGNY shares. BTIG Research upgraded shares of Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price target on the stock in a report on Monday, March 31st. JPMorgan Chase & Co. upped their target price on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Bank of America lifted their price target on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. Finally, Canaccord Genuity Group increased their price objective on Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a report on Friday, February 28th. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $23.64.

Progyny Stock Up 0.4 %

NASDAQ:PGNY opened at $22.34 on Friday. The company’s 50 day moving average is $22.01 and its 200-day moving average is $18.68. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $34.92. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of 38.52, a P/E/G ratio of 2.39 and a beta of 1.33.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.